# R1 Clinical-Safety Review — steroid_cell_tumor_ovary

VERDICT: APPROVE

goldens changed: no (intended: n/a — KB reference narrative, no engine/calculator/interaction logic touched)

Confidence: 90

## Summary
Clinically safe, dose-free, appropriately scoped as decision-support, and — critically — does
NOT mis-attribute any claim to DeVita. The draft's central integrity move is that it openly
states DeVita 12th ed. carries no dedicated section on this entity and labels every treatment
statement "general oncology standard, not from DeVita's section on this disease." No
adversarial-verify verdict file exists at the sidecar path, so there are no outstanding flagged
claims to reconcile.

## 1. Safety — PASS
No harmful, absolute, or overreaching statements. Surgical strategy is standard and correctly
tiered: fertility-sparing unilateral salpingo-oophorectomy for localised benign-appearing
disease; full staging for postmenopausal or malignant-feature tumours; cytoreduction + systemic
therapy reserved for metastatic/unresectable disease. Claims are hedged ("generally
sufficient", "where feasible"). Malignant-potential distinction (steroid cell tumour NOS vs
almost-always-benign stromal luteoma / Leydig cell tumour) is correct and drives appropriately
more intensive surveillance for the NOS subtype. No false-negative risk (no missed red flag,
no understated malignant potential).

## 2. Grounding — PASS
Treatment claims are consistent with standard gynae-oncology practice. The draft is
scrupulous about attribution: it notes DeVita describes platinum-taxane for epithelial ovarian
cancer and BEP (bleomycin-etoposide-cisplatin) for malignant germ cell / granulosa cell
tumours, then explicitly states neither passage refers to steroid cell tumour and neither
should be read as tumour-specific evidence. Platinum-based systemic therapy for malignant NOS
disease is correctly framed as an extrapolation, not a DeVita-grounded regimen. No fabricated
or outdated regimen. The "FLAG: needs manual sourcing" note against WHO Classification of
Female Genital Tumours is honest and correct.

## 3. Dose-free — PASS
No mg, mg/m2, AUC, numbered schedule, or cycle count. Regimen references are class/named-agent
only ("platinum-based combination", "platinum-and-taxane-based combination",
"bleomycin-etoposide-cisplatin combination") with zero numeric dosing. Compliant.

## 4. Scope — PASS
Framed as decision-support, not directive: repeated MDT referral, "individualised... on a
case-by-case basis", endocrinology referral for adrenal-source distinction. "Deliberately
omitted" section responsibly declines to generalise survival/response/recurrence figures from
differently-behaving tumour types.

## 5. Adversarial flags — N/A
No .verdict.md at the sidecar path; nothing to reconcile.

## Advisory (non-blocking)
- Monitoring lists serum testosterone/cortisol as the recurrence biomarker — correct for
  virilising/Cushingoid tumours, but a minority of steroid cell tumours are hormonally silent;
  a one-clause note that imaging surveillance carries recurrence detection when the tumour was
  non-secreting would round it out. Not required for approval.

No PHI touched; no AI-assisted generation flagged in scope — no downstream chaining required.
